• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ARID1A 和 PI3K 通路突变驱动的卵巢癌信号:改变是一个机会。

Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.

机构信息

Translational Oncology Laboratory, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

Department of Internal Medicine, SSOM, University of South Dakota, Sioux Falls, SD 57105, USA.

出版信息

Int J Mol Sci. 2019 Nov 15;20(22):5732. doi: 10.3390/ijms20225732.

DOI:10.3390/ijms20225732
PMID:31731647
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6888220/
Abstract

The chromosome is a functionally dynamic structure. The dynamic nature of chromosome functionally connects it to almost every event within a cell, in health and sickness. Chromatin remodeling system acts in unison with the cell survival pathway in mediating a variety of cellular functions, including mitosis, differentiation, DNA damage repair, and apoptosis. In humans, the 16 SWI/SNF complexes are a class of nucleosome remodelers, and ARID1A, an epigenetic tumor suppressor, is a member of mammalian 17 chromatin remodeling complex, SWI/SNF. Alterations of chromatin remodeling system contribute to tumorigenic events in various cancers, including ovarian cancers. Oncogenic changes of genes of the PI3K pathway are one of the potential genetic determinants of ovarian carcinomas. In this review, we present the data demonstrating the co-occurrence of mutations of ARID1A and the PI3K pathway in our cohort of ovarian cancers from the Avera Cancer Institute (SD, USA). Taking into account data from our cohort and the cBioPortal, we interrogate the opportunity provided by this co-occurrence in the context of mutation-driven signals in the life cycle of a tumor cell and its response to the targeted anti-tumor drugs.

摘要

染色体是一种具有功能的动态结构。染色体的动态性质使其与细胞内的几乎每一个事件都有功能上的联系,无论是在健康状态还是疾病状态下。染色质重塑系统与细胞存活途径协同作用,介导多种细胞功能,包括有丝分裂、分化、DNA 损伤修复和细胞凋亡。在人类中,16 个 SWI/SNF 复合物是一类核小体重塑因子,而 ARID1A,一种表观遗传肿瘤抑制因子,是哺乳动物 17 个染色质重塑复合物 SWI/SNF 的成员。染色质重塑系统的改变导致了多种癌症中的肿瘤发生事件,包括卵巢癌。PI3K 通路基因的致癌改变是卵巢癌的潜在遗传决定因素之一。在这篇综述中,我们展示了数据,证明了 ARID1A 和 PI3K 通路的突变在我们来自美国南达科他州 Avera 癌症研究所的卵巢癌队列中同时存在。考虑到我们队列和 cBioPortal 的数据,我们探讨了在肿瘤细胞生命周期中的突变驱动信号及其对靶向抗肿瘤药物的反应背景下,这种同时存在所提供的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/6888220/43038ac2d2f8/ijms-20-05732-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/6888220/dd74b61d4c62/ijms-20-05732-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/6888220/d5bc797c2033/ijms-20-05732-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/6888220/43038ac2d2f8/ijms-20-05732-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/6888220/dd74b61d4c62/ijms-20-05732-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/6888220/d5bc797c2033/ijms-20-05732-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/6888220/43038ac2d2f8/ijms-20-05732-g003.jpg

相似文献

1
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity.ARID1A 和 PI3K 通路突变驱动的卵巢癌信号:改变是一个机会。
Int J Mol Sci. 2019 Nov 15;20(22):5732. doi: 10.3390/ijms20225732.
2
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.ARID1A 表达缺失及其与卵巢透明细胞癌中 PI3K-Akt 通路改变和 ZNF217 扩增的关系。
Mod Pathol. 2014 Jul;27(7):983-90. doi: 10.1038/modpathol.2013.216. Epub 2013 Dec 13.
3
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.ARID1A 突变和 PI3K/AKT 通路改变在子宫内膜异位症和子宫内膜异位症相关卵巢癌中的作用。
Int J Mol Sci. 2013 Sep 12;14(9):18824-49. doi: 10.3390/ijms140918824.
4
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.利用合成致死和 DNA 损伤反应治疗 ARID1A 突变型癌症。
J Biomed Sci. 2022 Sep 19;29(1):71. doi: 10.1186/s12929-022-00856-5.
5
ARID1A-mutated ovarian cancers depend on HDAC6 activity.ARID1A基因发生突变的卵巢癌依赖于HDAC6的活性。
Nat Cell Biol. 2017 Aug;19(8):962-973. doi: 10.1038/ncb3582. Epub 2017 Jul 24.
6
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.ARID1A-PIK3CA共突变通过促肿瘤炎症细胞因子信号传导促进卵巢透明细胞肿瘤发生。
Nat Commun. 2015 Jan 27;6:6118. doi: 10.1038/ncomms7118.
7
ARID1A gene mutation in ovarian and endometrial cancers (Review).卵巢癌和子宫内膜癌中的ARID1A基因突变(综述)
Oncol Rep. 2016 Feb;35(2):607-13. doi: 10.3892/or.2015.4421. Epub 2015 Nov 16.
8
Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.染色质可及性是 ARID1A 突变型癌症中 SWI/SNF 亚基合成致死性的基础。
Elife. 2017 Oct 2;6:e30506. doi: 10.7554/eLife.30506.
9
The emerging roles of ARID1A in tumor suppression.ARID1A 在肿瘤抑制中的新兴作用。
Cancer Biol Ther. 2014 Jun 1;15(6):655-64. doi: 10.4161/cbt.28411. Epub 2014 Mar 11.
10
Targeting ARID1A mutations in cancer.靶向 ARID1A 突变治疗癌症。
Cancer Treat Rev. 2021 Nov;100:102287. doi: 10.1016/j.ctrv.2021.102287. Epub 2021 Sep 6.

引用本文的文献

1
Development of a streamlined NGS-based TCGA classification scheme for gastric cancer and its implications for personalized therapy.基于简化的二代测序(NGS)的胃癌TCGA分类方案的开发及其对个性化治疗的意义。
J Gastrointest Oncol. 2024 Oct 31;15(5):2053-2066. doi: 10.21037/jgo-24-345. Epub 2024 Sep 13.
2
ARID1A restrains EMT and stemness of ovarian cancer cells through the Hippo pathway.ARID1A 通过 Hippo 通路抑制卵巢癌细胞的 EMT 和干性。
Int J Oncol. 2024 Aug;65(2). doi: 10.3892/ijo.2024.5664. Epub 2024 Jun 14.
3
The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.

本文引用的文献

1
ARID1A promotes genomic stability through protecting telomere cohesion.ARID1A 通过保护端粒黏合促进基因组稳定性。
Nat Commun. 2019 Sep 6;10(1):4067. doi: 10.1038/s41467-019-12037-4.
2
Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers.系统分析 BAF 突变可深入了解人类癌症中复合物内的合成致死性。
Nat Genet. 2019 Sep;51(9):1399-1410. doi: 10.1038/s41588-019-0477-9. Epub 2019 Aug 19.
3
ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion.
染色质重塑复合物在卵巢癌中的新兴作用。
Int J Mol Sci. 2022 Nov 8;23(22):13670. doi: 10.3390/ijms232213670.
4
Roles of ARID1A variations in colorectal cancer: a collaborative review.ARID1A 变异在结直肠癌中的作用:合作综述。
Mol Med. 2022 Apr 14;28(1):42. doi: 10.1186/s10020-022-00469-6.
5
BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5.BRD9通过CANA2D4、CALML6、GNAO1和KCNJ5控制胃癌中的催产素信号通路。
Transl Cancer Res. 2020 May;9(5):3354-3366. doi: 10.21037/tcr.2020.03.67.
6
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.胆管癌中 ARID1A 和 PI3K/AKT 通路改变的治疗靶向。
PeerJ. 2022 Jan 13;10:e12750. doi: 10.7717/peerj.12750. eCollection 2022.
7
knockdown enhances carcinogenesis features and aggressiveness of Caco-2 colon cancer cells: An cellular mechanism study.敲低增强Caco-2结肠癌细胞的致癌特征和侵袭性:一项细胞机制研究。
J Cancer. 2022 Jan 1;13(2):373-384. doi: 10.7150/jca.65511. eCollection 2022.
ARID1A 和 PI3-kinase 通路突变在子宫内膜中驱动上皮细胞转分化和集体浸润。
Nat Commun. 2019 Aug 7;10(1):3554. doi: 10.1038/s41467-019-11403-6.
4
Molecular profiling and molecular classification of endometrioid ovarian carcinomas.子宫内膜样卵巢癌的分子谱分析和分子分类。
Gynecol Oncol. 2019 Sep;154(3):516-523. doi: 10.1016/j.ygyno.2019.07.012. Epub 2019 Jul 21.
5
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.肿瘤细胞中 ARID1A 的缺失使它们对联合电离辐射和 PARP 抑制剂治疗具有选择性易损性。
Clin Cancer Res. 2019 Sep 15;25(18):5584-5594. doi: 10.1158/1078-0432.CCR-18-4222. Epub 2019 Jun 13.
6
Fine-tuning of noise in gene expression with nucleosome remodeling.通过核小体重塑对基因表达中的噪声进行微调。
APL Bioeng. 2018 May 7;2(2):026106. doi: 10.1063/1.5021183. eCollection 2018 Jun.
7
Patient with anomalous skin pigmentation expands the phenotype of ARID2 loss-of-function disorder, a SWI/SNF-related intellectual disability.具有异常皮肤色素沉着的患者扩展了 ARID2 功能丧失障碍的表型,这是一种与 SWI/SNF 相关的智力障碍。
Am J Med Genet A. 2019 May;179(5):808-812. doi: 10.1002/ajmg.a.61075. Epub 2019 Mar 5.
8
Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.ARID1A 的功能丧失与胃癌中 PD-L1 的高表达密切相关。
Int J Cancer. 2019 Aug 15;145(4):916-926. doi: 10.1002/ijc.32140. Epub 2019 Feb 8.
9
Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.发现具有口服活性的 Brama 同源物(BRM)/SMARCA2 ATP 酶活性抑制剂,用于治疗 Brama 相关基因 1(BRG1)/SMARCA4 突变型癌症。
J Med Chem. 2018 Nov 21;61(22):10155-10172. doi: 10.1021/acs.jmedchem.8b01318. Epub 2018 Oct 31.
10
Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.从基因组学到卵巢透明细胞癌的免疫治疗:管理的独特机会。
Gynecol Oncol. 2018 Nov;151(2):381-389. doi: 10.1016/j.ygyno.2018.09.001. Epub 2018 Sep 12.